Obesity and Skin: Overview of the Moroccan Experience

Rachadi Z1*, Sebbani M2, Rafi S1, Elansari N1, Amine M3, Hocar O4, Amal S1

1Department of Dermatology, Mohamed VI Medical University Hospital, FMPM – UCA, Marrakech- Morocco
2Department of Public Health and Epidemiology, PCIM Laboratory, Mohamed VI Medical University Hospital, FMPM – UCA, Marrakech- Morocco
3Department of Endocrinology, Mohamed VI Medical University Hospital, FMPM – UCA, Marrakech- Morocco

Abstract

**Background:** Obesity is one of the world's biggest health problems nowadays. However, the impact of obesity on the skin has received minimal attention. **Objective:** To study the prevalence of skin manifestations in obese patients and also the correlation between severity of cutaneous involvement and the degree of obesity. **Methods:** We performed a case series, descriptive study, among 115 obese patients (BMI ≥ 30 kg/m²). All participants had benefited from a complete dermatological examination. A biological assessment for a metabolic syndrome was performed. The data analysis was performed using Fisher exact test, p-value and OR. **Results:** Common dermatoses seen in obese patients were acanthosis nigricans, striae, acrochordons, and various infections. They were correlated with the degree of obesity. **Conclusion:** Our work confirms the link between the severity of obesity and the prevalence of certain dermatological pathologies. Early recognition of these lesions may also warn patients of a need for weight loss. **Keywords:** Obesity, skin, acanthosis nigricans, striae, Morocco.

**METHODS**

The study was conducted in the Departments of Endocrinology and Dermatology, Mohamed VI Medical University Hospital, Marrakech- Morocco from May 2016 to May 2018.

The sample of 115 obese (BMI ≥ 30 kg/m²) was included in the study. Obese group was divided into three Body Mass Index (BMI) classes: class I (BMI 30-34.9 kg/m²), class II (BMI 35-39.9 kg/m²) and class III (BMI ≥ 40 kg/m²).

The clinical evaluation included detailed history, cutaneous and systemic examination. The Clinical parameters included weight, height, blood pressure, and waist circumference. For evaluation of underlying metabolic syndrome, certain lab investigations were carried out. This included fasting glucose, total cholesterol, and HDL and triglycerides levels. In patients with abnormal nails or skin lesions suggestive of superficial fungal infections, we performed fungal scarping and culture. Fungal smears were carried out to rule out tinea pedis as a cause of planar hyperkeratosis.
STATISTICAL ANALYSIS

All the data were entered in a pre-designed proforma. The analysis was descriptive at first, and comparative at the second time. The qualitative variables were compared using the Fisher’s exact test (frequencies of dermatoses among the three BMI groups of obese subjects), Odds Ratio (OR) were presented. A $p<0.05$ was considered significant.

RESULTS

The study population consisted of 115 obese patients. 100 females (87%) and 15 male (13%). The mean of age was 38.33 y [8-68 years], the mean of was 40.67 [30-63 kg/m²]. Obesity groups were distributed as follows : Class I : 22 patients, class II : 39 patients, class III : 54 patients. Systemic diseases in obese patient are presented in the Figure1. All co-morbid conditions like hypertension, diabetes, cardiopathy, and metabolic syndrome increase significantly with the degree of obesity.

The prevalence of dermatoses according to obesity grade are shown in Table 1, and the strength of association and statistical significance between dermatoses and the severity of obesity are shown in Table 2. The dermatoses that showed a significant association with obesity were acanthosis nigricans, chronic venous insufficiency, and various infectious especially onicomyces and intertrigo. However, diabetes were more associated with acanthosis nigricans and onychomycosis.

![Fig-1: Prevalence of co-morbid conditions correlating with the degree of obesity](image)

| Table-1: Prevalence of dermatoses according to obesity grade |
|---------------------------------------------------------------|
| **Dermatoses**       | **Class I (N = 22)** | **Class II (N = 39)** | **Class III (N = 54)** | **p-value** |
|----------------------|---------------------|----------------------|------------------------|-------------|
| Acanthosis nigricans | 23                  | 64,8                 | <0,001                 |             |
| Chronic venous insufficiency | 27,3 | 46,2                 | 75,9                   | NA*         |
| Lymphedema           | 4,5                 | 12,8                 | 22,2                   | <0,001      |
| Striae               | 63,6                | 79,5                 | 96,3                   | 0,001       |
| Acrochordons         | 22,7                | 51,3                 | 77,8                   | <0,001      |
| Folliculitis         | 31,8                | 41                   | 53,7                   | 0,179       |
| Boil                 | 18,2                | 10,3                 | 31,5                   | NA*         |
| Erysipelas           | 9,1                 | 7,7                  | 14,8                   | NA*         |
| Intertrigo           | 36,4                | 51,3                 | 83,3                   | <0,001      |
| Onicomyces           | 18,2                | 23,1                 | 55,6                   | 0,001       |
| Plantar hyperkeratosis | 13,63 | 25,64                 | 66                     | <0,001      |

*NA : Not Applicated
The link between obesity and skin infections is recognized in the literature [14]. Obesity increases the incidence of cutaneous infections, including candidiasis, intertrigo, folliculitis, furunculosis, erythrasma, tinea cruris, and folliculitis. Less common infections include erysipelas, cellulitis, necrotizing fasciitis, and gas gangrene. Although none of the following infectious complications are specific to obesity. Previous studies [15] have documented increased incidence within this population and clinical relevance. Changes in the skin barrier function, as well as alterations in the vascular microcirculation and the immune system, have been proposed as possible explanations altering host–organism dynamics and leading to fungal and bacterial infections in overweight or obese individuals [16]. 67% of patients had skin infections in the present study. Of these, 37% had onychomycosis, 45% had intertrigo and 25% had bacterial infections. A heightened awareness of these infections could lead to earlier diagnosis and treatment in an at-risk population [10].

Our study also found the greater prevalence of chronic venous insufficiency (CVD) in this population, and showed a statistical significance with the severity of obesity (OR = 0.206; p-value <0.001) Obesity has been supposed to be one of the main risk factors for Venous Insufficiency. Several studies have related CVD to obesity, and although many of them have shown a strong positive association, there still remains the question as to its role as a primary cause or as an aggravating factor in venous reflux. It has been observed that the CVD is more severe in obese patients, who frequently present more ulcers; these findings are consistent with the hypothesis that obesity worsens the clinical manifestations of CVD instead of starting it [17-19].

There is strong evidence for the role of obesity in cancer risk [20]. However, limited information is available on the potential link between obesity and either melanoma or non-melanoma skin cancers. In terms of the pathophysiological link between obesity and skin cancer, there is evidence that obesity-induced inflammation interacts with inflammation resulting from UV radiation to induce a state favorable to carcinogenesis. S. Pothiawala and al [21] have found in their prospective cohort that a BMI of 30 or greater is associated with a significantly lower risk of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) compared with a BMI in the range of 18.5–24.9. Overall, we did not find any strong association between BMI and the risk of melanoma.

### Table-2: Strength of association and statistical significance between dermatoses and obesity grade

| Dermatoses                        | Class I + II (N = 61) % | Class III (N = 54) % | OR*       | p-value** |
|-----------------------------------|-------------------------|----------------------|-----------|-----------|
| Acanthosis nigricans              | 14.8                    | 64.8                 | 0.094     | <0.001    |
| chronic venous insufficiency      | 39.3                    | 63.1                 | 0.206     | <0.001    |
| Lymphedema                       | 9.8                     | 22.2                 | 0.382     | 0.068     |
| Plantar hyperkeratosis            | 18.5                    | 68.5                 | 0.101     | <0.001    |
| Striae                           | 73.8                    | 96.3                 | 0.108     | 0.001     |
| Acrochordons                      | 41.0                    | 77.8                 | 0.198     | <0.001    |
| Erysipelas                        | 8.2                     | 14.8                 | 0.513     | 0.263     |
| Intertrigo                        | 45.9                    | 83.3                 | 0.170     | <0.001    |
| Onicomyceses                      | 21.3                    | 55.6                 | 0.217     | <0.001    |

*OR = Odds Ratio
**Significance obtained by Fisher’s exact test
Skin care in obese patients deserves special attention, not only because such patients have diseases that are susceptible to treatment, but also due to higher morbidity in this population [22]. Dermatoses as acrochordons and pseudoacanthosis nigricans are related to endocrine disorders and should be investigated [23]. Attention needs to be paid to the increased risk of skin infections and lymphedema in the obese patients. Dermatologists need to be aware of the skin diseases related to obesity and their impact on the patient’s life.

**CONCLUSION**

Our work confirms the link between the severity of obesity and the prevalence of certain dermatological pathologies, which is consistent with the results of the series of the literature. An understanding and a thorough knowledge of these skin disorders are necessary for dermatologists, because several dermatoses are treatable, thus improving the quality of life of the patient.

**REFERENCES**

1. Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in the United States. Obes Rev. 2005; 6: 5–7.
2. https://www.hcp.ma/
3. Bays HE, Gonzalez-Campoy JM, Bray GA. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. *Expert Rev Cardiovasc Ther.* 2008; 6:343–368.
4. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. *J Am Acad Dermatol.* 2007; 56:901–916; quiz 917–920.
5. Shipman AR, Millington GW. Obesity and the skin. *Br J Dermatol.* 2011;165:743–750.
6. Scheinfeld NS. Obesity and dermatology. *Clin Dermatol.* 2004;22:303–309.
7. Mathur AN, Goebel L. Skin findings associated with obesity. *Adolesc Med State Art Rev.* 2011;22:146–156, ix.
8. Garcia Hidalgo L. Dermatological complications of obesity. *Am J Clin Dermatol.* 2002; 3:497–506.
9. Mori. Characterization of skin function associated with obesity and specific correlation to local/systemic parameters in American women Lipids in Health and Disease. 2017; 16:214
10. Yosipovitch, De Vore and Dawn. Obesity and the skin: Skin physiology and skin manifestations of obesity. *J Am Acad Dermatol.* 2007; 56 :6
11. Strumia R. Dermatologic signs in patients with eating disorders. *Am J Clin Dermatol* 2005; 6: 165–173.
12. Hermans-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. *Am J Clin Dermatol.* 2004; 5:199–203.
13. Hud JA Jr, Cohen JB, Wagner JM, Cruz PD Jr. Prevalence and significance of acanthosis nigricans in adult obese population. *Arch Dermatol.* 1992; 12:941-4.
14. Al-Mutairi N. Associated cutaneous diseases in obese adult patients: a prospective study from a skin referral care center. Med Princ Pract. 2011; 20: 248–252.
15. Boza JC and al. Skin manifestations of obesity: a comparative study. *J Eur Acad Dermatol Venereol.* 2012 Oct;26(10):1220-3
16. Guida B, Nino M, Perrino NR. The impact of obesity on skin disease and epidermal permeability barrier status. *J Eur Acad Dermatol Venereol.* 2010; 24:191–195.
17. Van Rij AM, De Alwis CS, Jiang P. Obesity and impaired venous function. *Eur J Vasc Endovasc Surg.* 2008; 35: 739–744.
18. Musil D, Kalentova M and Herman J. Age, body mass index and severity of primary chronic venous disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech. Repub. 2011; 155: 367–372.
19. AC Seidel, CEQ Belczak, MB Campos, RB Campos and DS Harada. The impact of obesity on venous insufficiency. *Phlebology. 2015 Aug; 30(7):475-80
20. Renehan AG, Tyson M, Egger M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet.* 2008; 371:569–578.
21. Pothiawala S, Qureshi AA, Li Y, Han J. Obesity and the incidence of skin cancer in US Caucasians. *Cancer Causes Control.* 2012 May;23(5):717-26
22. Boza JC, Rech L, Sachett L, Menegon DB, Cestari TF. Skin manifestations of obesity. *Rev HCPA.* 2010; 30: 55–62.
23. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. *Am J Clin Dermatol.* 2003; 4: 315–331.